Myeloma
If it’s your first time on this website, please read the disclaimer section.
May 18 – May 25, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This phase III GMMG-HD7 trial evaluated MALDI-TOF mass spectrometry (MS) for minimally invasive detection of monoclonal proteins in 617 patients with newly diagnosed multiple myeloma. MS demonstrated superior sensitivity over serum protein electrophoresis and provided strong prognostic value, with MS negativity at 12 months of maintenance significantly improving progression-free survival (HR 0.25; 95% CI, 0.15–0.43). The study highlights that combining serum MS with bone marrow measurable residual disease (MRD) assessments refines risk stratification and identifies patients at highest risk for relapse. These findings support integrating MS as a reproducible, practical biomarker for longitudinal cancer monitoring and potential risk-adapted treatment strategies in clinical practice.
10.1200/JCO-25-02957
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This abstract describes the ASCO Living Guideline for the Treatment of Multiple Myeloma, a specific cancer. These guidelines are developed by a standing expert panel through continuous systematic review of rapidly evolving evidence to provide updated clinical practice recommendations. The abstract outlines the methodology and purpose of these dynamic guidelines, emphasizing their regular updates and their role as a continuously evolving resource. While not presenting specific clinical findings, it highlights the importance of evidence-based, frequently updated guidance for cancer treatment, reminding clinicians that guidelines supplement, not replace, professional judgment.
10.1200/JCO-26-01139
Apr 27 – May 04, 2026
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This randomized, placebo-controlled trial evaluated whether prophylactic B-cell depletion with obinutuzumab could prevent corticosteroid-requiring chronic graft-versus-host disease (cGVHD) in 178 allogeneic transplant recipients. Obinutuzumab significantly reduced the 1-year incidence of steroid-requiring cGVHD to 13.3% compared to 35.2% in the placebo group (p=0.0005) and improved 2-year immunosuppression-free, relapse-free survival (48% vs. 34%). While the study focuses on a post-transplant complication, the findings are highly relevant for clinicians managing hematologic malignancies where cGVHD remains a major barrier to successful recovery. These results suggest that early B-cell depletion is an effective strategy for reducing morbidity and improving long-term outcomes in high-risk cancer patients undergoing transplantation.
10.1200/JCO-25-03104
Apr 20 – Apr 27, 2026
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This expert opinion paper reviews the diagnostic and therapeutic management of various hematologic malignancies diagnosed during pregnancy, addressing the increasing global incidence in this population. The authors evaluate the safety and efficacy of diagnostic modalities and treatment options, including chemotherapy, radiation therapy, and immunotherapy, for conditions such as acute leukemia and lymphomas. It provides clinical guidance on balancing maternal oncological care with fetal safety, emphasizing that more women are now receiving adequate treatment without compromising pregnancy outcomes. The findings suggest that multidisciplinary approaches allow for expanded treatment possibilities, though specific numerical survival data were not provided in this qualitative expert consensus.
10.1200/JCO-25-02351
Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This retrospective cohort study compared two definitions of high-risk smoldering multiple myeloma (SMM) to identify which best predicts progression to active multiple myeloma. Using data from a screened cohort (iStopMM, n=193) and a clinical cohort (DALY-CARE, n=1147), the AQUILA criteria classified 34-55% of patients as high-risk, while the 2/20/20 model identified only 8-19%. The 2/20/20 model captured a higher 2-year progression risk (44.1% vs 27.0%) and annual progression rate (27.3% vs 14.5%), indicating it more accurately isolates truly high-risk patients. The findings directly support using the 2/20/20 model to guide early intervention decisions in SMM, a cancer precursor.
10.1001/jamaoncol.2026.0831
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This phase 1 trial evaluated the safety and efficacy of ESO-T01, an immune-shielded lentiviral vector designed to generate anti-BCMA CAR-T cells directly in vivo for patients with relapsed or refractory multiple myeloma. Among five heavily pretreated patients, four achieved objective responses, including three stringent complete remissions and 100% (4/4) minimal residual disease negativity by day 60. While all patients experienced grade 3 or higher adverse events, including cytokine release syndrome in 80% of participants, no dose-limiting toxicities were observed despite the absence of lymphodepleting chemotherapy. These results demonstrate the preliminary feasibility of bypassing complex ex vivo manufacturing, potentially streamlining access to advanced cellular immunotherapy for hematologic malignancies.
10.1038/s41591-026-04244-6